The problem. Artemisinin is the frontline antimalarial, but it was sourced from a plant (Artemisia annua) with volatile supply and price. Could you engineer a microbe to make it — the proof that synthetic biology yields products, not just papers?

The idea. Ro et al. engineered Saccharomyces cerevisiae to produce artemisinic acid, a precursor a few chemical steps from artemisinin. They up-regulated the yeast mevalonate pathway to flood the cell with the isoprenoid building block (FPP), expressed amorphadiene synthase to cyclize it into the artemisinin scaffold, and — the linchpin — identified and expressed a novel cytochrome P450 (CYP71AV1) from A. annua that oxidizes amorphadiene to artemisinic acid, which the yeast conveniently secretes. It’s a masterclass in metabolic engineering: redirect flux, add the committed step, add the tailoring enzyme.

Why it matters. This is the origin story behind Amyris and the later semisynthetic-artemisinin program, and it’s the paper any positioning argument about synbio’s commercial value has to reckon with. It grounds the abstract promise in one concrete, high-stakes molecule.

Verdict. A genuine landmark — and the most instructive part is what came after the paper. Getting from artemisinic acid to cost-competitive drug took roughly another decade, large public/philanthropic investment, and ultimately ran into the economics of cheap plant-derived supply. The honest lesson for a modern tooling pitch: the science was necessary but not sufficient; scale-up, economics, and timelines dominate — and it’s exactly those later stages where today’s design models and automation would most change the math.